# A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

> **NCT04119453** · PHASE2 · TERMINATED · sponsor: **Elevar Therapeutics** · enrollment: 80 (actual)

## Conditions studied

- Adenoid Cystic Carcinoma

## Interventions

- **DRUG:** Rivoceranib

## Key facts

- **NCT ID:** NCT04119453
- **Lead sponsor:** Elevar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-22
- **Primary completion:** 2023-06-28
- **Final completion:** 2023-06-28
- **Target enrollment:** 80 (ACTUAL)
- **Why stopped:** The RM-202 study was terminated by the Sponsor due to redirection of the rivoceranib development plan.
- **Last updated:** 2024-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04119453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04119453, "A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04119453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*